<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534819</url>
  </required_header>
  <id_info>
    <org_study_id>Anchor Post Market Registry</org_study_id>
    <nct_id>NCT01534819</nct_id>
  </id_info>
  <brief_title>ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)</brief_title>
  <acronym>ANCHOR</acronym>
  <official_title>Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ANCHOR registry is a multi-center, post-market, non-interventional, non-randomized,
      prospective study.

      Subjects must sign an ICF prior to obtaining any study specific information. Subjects are
      eligible to be consented up to 30 days post-procedure.

      Enrolled subjects will be followed as per local 'standard of care' for up to 5 years post
      procedure. Study recommended follow-up is per SVS and ESVS guidance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the ANCHOR registry is to expand the clinical knowledge based on the use of
      the Heli-FX™ EndoAnchor™ System. This registry will include &quot;real world&quot; use over a broad
      spectrum of geographies, by a wide variety of practicing clinicians, and with a minimal
      degree of subject selection criteria.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Anticipated">December 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Protocol B has composite primary safety endpoints, tabulated separately for the abdominal, thoracic and advanced disease arms</measure>
    <time_frame>Through 12 months</time_frame>
    <description>The primary safety endpoint is defined by:
i. freedom from device-related serious adverse events at 12 months and ii. freedom from procedure-related serious adverse events at 12 months iii. freedom from aneurysm-related mortality defined as: i. death within 30 days of the index procedure ii. death within 30 days of a secondary procedure to address the aneurysm iii. death from rupture of the treated aneurysm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol B has composite primary effectiveness endpoints, tabulated separately for the abdominal, thoracic and advanced disease arms</measure>
    <time_frame>Through 12 months</time_frame>
    <description>The primary effectiveness endpoint requires all of the following:
i successful implantation of the minimum number of EndoAnchor™ and ii freedom from migration at 12 months and iii freedom from Type I endoleak at the targeted attachment site(s) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol C has composite primary safety endpoint</measure>
    <time_frame>Through 12 months</time_frame>
    <description>The primary safety endpoint is defined by:
device-related serious adverse events at 12 months
aneurysm-related mortality defined as:
i. death within 30 days of the index procedure ii. death within 30 days of a secondary procedure to address the aneurysm iii. death from rupture of the treated aneurysm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol C have composite primary effectiveness endpoint</measure>
    <time_frame>Through 12 months</time_frame>
    <description>The primary effectiveness endpoint is treatment success which is defined as the successful implantation of EndoAnchor™ implants at the index procedure, and the absence of:
migration at 12 months and
Type I endoleak at the targeted attachment site(s) at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protocol B has the secondary endpoints chosen to reflect the clinical success and safety of Heli-FX™. Each of the secondary endpoints will be measured individually at 30 days and 12 months and yearly thereafter.</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Technical success defined as successful deployment of EndoAnchor™ at their intended location. Technical success will be assessed separately for the target attachment sites; proximally and/or distally
Clinical success will be defined as the successful implantation of the suggested number of EndoAnchor™ at the index procedure, and the absence of: death as a result of aneurysm-related treatment; Type Ia endoleak; Type Ib endoleak (TAA and advanced disease only); endograft infection; endograft migration; loss of endograft fabric integrity as a result of the EndoAnchor™; Rupture of the treated aneurysm; Conversion to open surgical repair
Secondary aneurysm-related interventions after EndoAnchor™ implantation
all-cause mortality
Freedom from EndoAnchor™ fracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol C has the secondary endpoints chosen to reflect the clinical success and safety of Heli-FX™. Each of the secondary endpoints will be measured individually at 30 days and 12 months and yearly thereafter.</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Technical success defined as successful deployment of EndoAnchor™ at their intended location. Technical success will be assessed separately for the target attachment sites; proximally and/or distally
Clinical success will be defined as the successful implantation of EndoAnchor™ at the index procedure, and the absence of: aneurysm-related mortality; Type Ia endoleak; endograft infection; endograft migration; loss of endograft fabric integrity as a result of the EndoAnchor™; Rupture of the treated aneurysm; Conversion to open surgical repair
Secondary aneurysm-related interventions after EndoAnchor™ implantation
all-cause mortality
EndoAnchor™ implant fracture</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">1090</enrollment>
  <condition>Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Protocol B, abdominal arm, revision group</arm_group_label>
    <description>AAA subjects with previously implanted commercial endografts for the treatment of graft migration and/or Type Ia endoleak</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol B, abdominal arm, primary group</arm_group_label>
    <description>AAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type Ia endoleak, or to treat Type Ia endoleak evident at the time of implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol B, thoracic arm, revision group</arm_group_label>
    <description>TAA subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol B, thoracic arm, primary group</arm_group_label>
    <description>TAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol B, advanced disease arm, revision group</arm_group_label>
    <description>Advanced disease subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol B, advanced disease arm, primary group</arm_group_label>
    <description>Advanced disease subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol C, abdominal arm, short neck, primary group</arm_group_label>
    <description>Planned use of Heli-FX™ in conjunction with the Endurant II/IIs endograft in AAA subjects with short proximal necks (≥ 4 mm and &lt; 10 mm) in primary group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoAnchor™</intervention_name>
    <description>Use of the EndoAnchor™ in conjunction with endograft</description>
    <arm_group_label>Protocol B, abdominal arm, primary group</arm_group_label>
    <arm_group_label>Protocol B, abdominal arm, revision group</arm_group_label>
    <arm_group_label>Protocol B, advanced disease arm, primary group</arm_group_label>
    <arm_group_label>Protocol B, advanced disease arm, revision group</arm_group_label>
    <arm_group_label>Protocol B, thoracic arm, primary group</arm_group_label>
    <arm_group_label>Protocol B, thoracic arm, revision group</arm_group_label>
    <arm_group_label>Protocol C, abdominal arm, short neck, primary group</arm_group_label>
    <other_name>Heli-FX™</other_name>
    <other_name>Heli-FX™ EndoAnchor™ System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular treament</intervention_name>
    <description>implantation of a device inserted through an artery</description>
    <arm_group_label>Protocol B, abdominal arm, primary group</arm_group_label>
    <arm_group_label>Protocol B, abdominal arm, revision group</arm_group_label>
    <arm_group_label>Protocol B, advanced disease arm, primary group</arm_group_label>
    <arm_group_label>Protocol B, advanced disease arm, revision group</arm_group_label>
    <arm_group_label>Protocol B, thoracic arm, primary group</arm_group_label>
    <arm_group_label>Protocol B, thoracic arm, revision group</arm_group_label>
    <arm_group_label>Protocol C, abdominal arm, short neck, primary group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Protocol B: subjects with AAA, TAA, or advanced aortic aneurysmal disease treated with the
        Heli-FX™ EndoAnchor™ System in conjunction with commercially available abdominal and
        thoracic Endografts, in both &quot;Primary&quot; and &quot;Revision&quot; settings and who meet the
        inclusion/exclusion criteria.

        Protocol C:The intended population will include those subjects with short (≥ 4 mm and &lt; 10
        mm) infrarenal proximal neck lengths who are appropriate candidates for infrarenal AAA
        treatment with the Heli-FX™ EndoAnchor™ System in conjunction with the Endurant II/IIs
        endograft system and who meet the inclusion/exclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Protocol B:

        Inclusion criteria:

          1. Subjects with asymptomatic, symptomatic, or ruptured aortic aneurysms

          2. Subject ≥ 18 years old

          3. Subject has provided written informed consent, either before or less than or equal to
             30 calendar days after the index procedure

          4. Subject is willing and able to comply with standard of care followup evaluations

          5. Subject has a previously implanted endograft or will be undergoing repair, with one of
             the following aortic aneurysm endograft devices:

               -  Cook Zenith or Cook Zenith TX2

               -  Gore Excluder or TAG

               -  Medtronic AneuRx

               -  Medtronic Talent

               -  Medtronic Endurant or Valiant

               -  Any additional third party AAA endograft device that is commercially available
                  and listed as compatible with Heli-FX™ in the IFU

          6. Subject's iliac/femoral access is compatible with:

               -  a 16 French sheath (abdominal subjects)

               -  18 French sheath (thoracic subjects)

               -  Selected 16 or 18 French sheath, as applicable to the device selected for use
                  (advanced disease subjects)

          7. Subject has a previously implanted endograft that has migrated or has a Type I
             endoleak within the aorta or will undergo implantation of an endograft that in the
             opinion of the investigator will be at increased risk of such complications

        Exclusion criteria:

          1. Subject has known allergy to the EndoAnchor™ implant material (nickel, chromium,
             molybdenum, or cobalt)

          2. Subject has a life expectancy of less than 1 year

          3. Subject is participating in a clinical study or registry that, in the Investigator's
             opinion, may conflict or may have a negative impact on the subject's safety

          4. Subject was treated with EndoAnchor™ in the same segment of the aorta that will be
             treated in the registry

          5. Subject has an active or known history of bleeding diathesis

          6. Subject has a condition that threatens to infect the endograft (active bacteremia, or
             infections that carry increased risk of endograft infection)

          7. Significant thrombus or calcium at the location of planned EndoAnchor™ implantation
             that precludes adequate EndoAnchor™ penetration of the aortic wall

          8. Use where, for whatever reason, each EndoAnchor™ is not anticipated to adequately
             penetrate into the aortic wall

          9. Subject has an aortic dissection that involves an area to be treated with EndoAnchor™

         10. Subject has Marfan Syndrome, Ehlers Danlos Syndrome, or another collagen vascular
             disease

         11. Subject is pregnant

        Protocol C:

        Inclusion criteria:

          -  Subjects with asymptomatic or symptomatic abdominal aortic aneurysms that will receive
             the Heli-FX™ in conjunction with the Endurant II/IIs endograft as part of their
             planned EVAR treatment

          -  Subject ≥ 18 years old

          -  Subject has provided written informed consent, either before or less than or equal to
             30 calendar days after the index procedure

          -  Subject is willing and able to comply with standard of care followup evaluations

          -  Subject will be undergoing AAA repair with the bifurcated main body Endurant II/IIs
             stent graft in conjunction with Heli-FX™ with a proximal neck length of ≥ 4mm to &lt;
             10mm and treated in accordance with the Endurant II/IIs and Heli-FX™ IFUs

          -  Subject's iliac/femoral access is compatible with a 16 French sheath

        Exclusion criteria:

          -  Subject has known allergy to the EndoAnchor™ implant material (nickel, chromium,
             molybdenum, or cobalt)

          -  Subject has a life expectancy of less than 1 year

          -  Subject is participating in a clinical study or registry that, in the Investigator's
             opinion, may conflict or may have a negative impact on the subject's safety

          -  Subject was previously treated with EndoAnchor™ implants in the same segment of the
             aorta that will be treated within the registry, or has a previously implanted AAA
             endograft that has migrated or has a Type Ia endoleak, or is being treated for a
             ruptured abdominal aortic aneurysm, or has planned usage of an Endurant II/IIs AUI
             main body stent graft configuration

          -  Subject has an active or known history of bleeding diathesis

          -  Subject has a condition that threatens to infect the endograft (active bacteremia, or
             infections that carry increased risk of endograft infection)

          -  Significant thrombus or calcium at the location of planned EndoAnchor™ device
             implantation that precludes adequate EndoAnchor™ implant penetration of the aortic
             wall

          -  Use where, for whatever reason, each EndoAnchor™ implant is not anticipated to
             adequately penetrate into the aortic wall

          -  Subject has an aortic dissection that involves an area to be treated with EndoAnchor™
             implants

          -  Subject has Marfan Syndrome, Ehlers Danlos Syndrome, or another collagen vascular
             disease

          -  Subject is pregnant

          -  Physician does not intend to treat subject on-label per the Endurant II/IIs and
             Heli-FX™ IFU requirements or if the physician intends to use Heli-FX™ in a chimney
             procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul de Vries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Medisch Centrum Groningen, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Jordan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University, United States</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abrazo Arizona Heart Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>84006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John L McClellan Memorial Veterans Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Loma Linda Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502-2004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital Vascular Surgery Dept.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac &amp; Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Moanalua Medical Center and Clinic</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HeartCare Midwest</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess-Harvard</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>98507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Barnes Jewish West County Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Health Partners</name>
      <address>
        <city>Queensbury</city>
        <state>New York</state>
        <zip>12804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina (UNC) Memorial Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle Harrisburg Campus</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexington Medical Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Memorial Hospital Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital-Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic and Vascular Surgeons</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center, University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <zip>NSW 2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dandenong Hospital</name>
      <address>
        <city>Dandenong</city>
        <zip>VIC 3175</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>WA 6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <zip>NSW 2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus - Universitätskliniken Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitätskliniken Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät der RWTH</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bonifatius Hospital</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Kilinikum der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Franzsikus-Hospital GmbH</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuremberg</name>
      <address>
        <city>Nuremberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Universitaria Policlinico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unihospital San Giovanni di Dio Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Siena</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ordine Mauriziano di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny ustav srdcovych a cievnych chorob</name>
      <address>
        <city>Nové Mesto</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thorax Institute Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia / San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malmo University Hospital</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Liverpool and NHS Broadgreen University Hospitals - Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <link>
    <url>http://www.medtronic.com</url>
    <description>Medtronic</description>
  </link>
  <results_reference>
    <citation>Jordan WD Jr, Mehta M, Varnagy D, Moore WM Jr, Arko FR, Joye J, Ouriel K, de Vries JP; Aneurysm Treatment using the Heli-FX Aortic Securement System Global Registry (ANCHOR) Workgroup Members. Results of the ANCHOR prospective, multicenter registry of EndoAnchors for type Ia endoleaks and endograft migration in patients with challenging anatomy. J Vasc Surg. 2014 Oct;60(4):885-92.e2. doi: 10.1016/j.jvs.2014.04.063. Epub 2014 Jul 31.</citation>
    <PMID>25088739</PMID>
  </results_reference>
  <results_reference>
    <citation>Jordan WD Jr, Mehta M, Ouriel K, Arko FR, Varnagy D, Joye J, Moore WM Jr, de Vries JP. One-year results of the ANCHOR trial of EndoAnchors for the prevention and treatment of aortic neck complications after endovascular aneurysm repair. Vascular. 2016 Apr;24(2):177-86. doi: 10.1177/1708538115590727. Epub 2015 Jun 10.</citation>
    <PMID>26069087</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endograft</keyword>
  <keyword>Endurant</keyword>
  <keyword>Heli-FX™</keyword>
  <keyword>EndoAnchor™</keyword>
  <keyword>Short neck</keyword>
  <keyword>Endovascular treatment</keyword>
  <keyword>Interventional treatment of aortic aneurysm</keyword>
  <keyword>Abdominal aortic aneurysm</keyword>
  <keyword>AAA</keyword>
  <keyword>Thoracic aortic aneurysm</keyword>
  <keyword>TAA</keyword>
  <keyword>Advanced disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

